StrideBio, Inc

StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond. We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBio’s AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.

Website

http://www.stridebio.com

External link for StrideBio, Inc

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Durham, North Carolina

Type

Privately Held

Founded

2015

Specialties

Gene Therapy, AAV Vectors, and Biotechnology